Arch Biopartners (TSXV:ARCH) Cash-to-Debt : 0.06 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Arch Biopartners's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.06.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Arch Biopartners couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Arch Biopartners's Cash-to-Debt or its related term are showing as below:

TSXV:ARCH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.19 Max: No Debt
Current: 0.06

During the past 13 years, Arch Biopartners's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 0.19.

TSXV:ARCH's Cash-to-Debt is ranked worse than
96.03% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs TSXV:ARCH: 0.06

Arch Biopartners Cash-to-Debt Historical Data

The historical data trend for Arch Biopartners's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Arch Biopartners Cash-to-Debt Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

Get a 7-Day Free Trial

0.14

0.19

0.09

0.12

0.17

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.04	0.12	0.28	0.17	0.06

Competitive Comparison of Arch Biopartners's Cash-to-Debt

For the Biotechnology subindustry, Arch Biopartners's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Biopartners's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Cash-to-Debt falls into.

Arch Biopartners Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Arch Biopartners's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.831	/	(4.312	+	0.704)
	=	0.17

Arch Biopartners's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.303	/	(4.537	+	0.5)
	=	0.06

Arch Biopartners (TSXV:ARCH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Arch Biopartners Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.